BrainsWay
Company · Jerusalem, Israel
Developed Deep TMS (H-coil), FDA-cleared for depression, OCD and smoking cessation.
In the news
NeuromodulationIndustry
BrainsWay says US insurance coverage for Deep TMS in OCD passes 118 million people
BrainsWay reports that medical policies covering its Deep TMS treatment for obsessive-compulsive disorder now reach more than 118 million Americans.
ResearchNeuromodulation
Study: suicidal thoughts fell 70% during Deep TMS treatment for depression
A secondary analysis of 89 patients found faster improvement with BrainsWay's accelerated SWIFT protocol than with standard daily sessions.
RegulationNeuromodulation
BrainsWay's Deep TMS cleared for depression in people aged 15 to 21
The FDA clearance for adolescent depression as an add-on therapy was based on real-world data from more than 1,100 young patients.